Research programme: TIGIT antagonist monoclonal antibodies - iTeos Therapeutics

Drug Profile

Research programme: TIGIT antagonist monoclonal antibodies - iTeos Therapeutics

Alternative Names: TIGIT antagonist monoclonal antibody - iTeos Therapeutics

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iTeos Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Jan 2018 A lead candidate will enter a phase I trial in Cancer in the first half of 2019 (iTeos Therapeutics Pipeline, January 2018)
  • 10 Jan 2018 Preclinical trials in Cancer in Belgium (Parenteral) before January 2018 (iTeos Therapeutics Pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top